Zoon Kathryn C 4

What Happened
Kathryn C. Zoon, a member of Emergent BioSolutions' board of directors, sold 17,202 shares in open-market transactions on May 1, 2026 for total proceeds of $144,453, and on April 30, 2026 received equity awards: 25,344 restricted stock units (RSUs) and 11,296 stock options (both reported as acquired at $0.00). The share sales were executed under a Rule 10b5-1 trading plan to cover tax obligations related to RSU vesting.

Key Details

• Sale date(s): May 1, 2026.
  • 16,145 shares sold at a weighted-average price of $8.36 (range $7.77–$8.70) for $134,972. (F3)
  • 1,057 shares sold at a weighted-average price of $8.97 (range $8.79–$8.99) for $9,481. (F4)
• Awards (reported April 30, 2026): 25,344 RSUs (F1) and 11,296 stock options (derivative award; F5/F6).
• Reason for sale: Shares sold pursuant to a Rule 10b5-1 plan dated May 16, 2025 to satisfy tax obligations from RSU vesting on April 29, 2026. (F2)
• Vesting/terms: RSUs vest on the day prior to the one-year anniversary of the grant (Annual Grant Vesting Date), subject to continued board service. Options vest on the same Annual Grant Vesting Date; option count was determined per the plan formula using a Black‑Scholes valuation (F1, F5, F6).
• Shares owned after transaction: not specified in this filing.

Context
These transactions combine routine board compensation (annual RSU and option grants) and a pre-existing 10b5-1 sale plan used to meet tax withholding from RSU vesting. Sales under an established 10b5-1 plan are generally considered routine and do not necessarily indicate a change in the insider’s view of the company.